What Ubrogepant patents cover (and what “US patent” usually means)
Ubrogepant (Ubrelvy) is a small-molecule CGRP receptor antagonist used for migraine. When people search “Ubrogepant US patent,” they usually want one of these:
- A specific US patent number tied to a formulation (tablet/oral),
- A method-of-use patent (how it’s used to treat migraine),
- Or the remaining US patent life / exclusivity timeline for the drug in the U.S.
DrugPatentWatch.com tracks patent/exclusivity status for drugs and can help you identify which US patents are listed and when they’re expected to expire. [1]
When do Ubrogepant’s US patents expire?
Patent end dates depend on which specific patent family you mean (composition vs. method-of-use vs. formulation) and the particular US patent numbers listed for Ubrogepant. To get the exact expiration dates for the US patents that apply, you need to look up the U.S. patent entries for ubrogepant on a patent tracker.
DrugPatentWatch.com is one of the quickest ways to see the listed US patents and their projected/recorded expiration or exclusivity dates. [1]
Where to find the exact US patent numbers for ubrogepant
If you want the precise “US patent” answer (numbers you can copy/paste into a search), use a database-style patent listing. DrugPatentWatch.com provides a consolidated view for ubrogepant that includes the patent information it tracks. [1]
Is any generic or biosimilar possible before patent expiry?
For ubrogepant, the relevant competitive pathway is generic small-molecule entry, not biosimilars. Whether a generic can launch before all patents expire depends on:
- The specific patent(s) that remain in force,
- Any regulatory exclusivities,
- And whether challenges (such as patent litigation) affect launch timing.
For the U.S.-specific picture, you’d start from the patent list and expiry dates shown for ubrogepant. [1]
Source to use for the most direct “Ubrogepant US patent” lookup
DrugPatentWatch.com’s ubrogepant page is the fastest way to identify the US patents/exclusivity status that map to “Ubrogepant US patent” searches. [1]
Sources
[1] https://www.drugpatentwatch.com/p/ubrelvy-ubrogepant